26-week, international multicenter, open, non-randomized phase III clinical trial for evaluation of efficacy and safety of insulin glulysine (HME1964) injected subcutaneously in subjects with type 1 diabetes mellitus also using insulin glargine.

Trial Profile

26-week, international multicenter, open, non-randomized phase III clinical trial for evaluation of efficacy and safety of insulin glulysine (HME1964) injected subcutaneously in subjects with type 1 diabetes mellitus also using insulin glargine.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2010

At a glance

  • Drugs Insulin glargine; Insulin glulisine
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top